BioTek Receives 2014 Supplier of the Year Award from Fisher Scientific
News Mar 25, 2015
BioTek Instruments, a global leader in microplate instrumentation technology, recently received the '2014 Supplier of the Year' award from Fisher Scientific, part of Thermo Fisher Scientific. The award was presented to BioTek in Phoenix, Arizona at Fisher Scientific’s annual meeting.
Fisher Scientific annually presents this award to the supplier that best exemplifies outstanding overall performance and support in a number of categories including percent growth, marketing participation, new product development and on time delivery to help grow Fisher’s North American business. This prestigious award was presented by David Koi, Senior Vice President, Global Portfolio Management and Lisa Witte, President, Research & Safety Division at Fisher Scientific.
"Our goal is to ensure that our customers - and our channel partners – consistently receive outstanding pre- and post-sale customer support. We are honored that Fisher Scientific would recognize our efforts to reach this goal," commented Gary Barush, Global Director of Marketing and Sales at BioTek Instruments. "The entire BioTek team shares in this award, and we look forward to growing our strong relationship with Fisher Scientific."
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. These technologies are used to aid life science research, facilitate drug discovery, provide rapid and cost-effective analysis, and enable sensitive, accurate quantification of molecules across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations. As such, they are often honored for local accomplishments and technological innovations, including Best Places to Work in Vermont, North American New Product Innovation Award for Workflow Solutions in Life Sciences and Drug Discovery Product of the Year — Scientists' Choice Award.
UCL Technology Fund Investment MeiraGTx Raises $75 Million in IPONews
MeiraGTx Holdings plc raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO).READ MORE
A Mechanism of Drug Resistance in Breast & Ovarian CancerNews
Researchers have discovered the molecular means by which some cancers caused by errors in the gene BRCA1 evade treatment by drugs custom-tailored to kill them.READ MORE
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019